Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein

[1]  Thomas Hummel,et al.  Olfactory loss may be a first sign of idiopathic Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[2]  G. Muntané,et al.  Abnormal α-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease , 2006, Neuroscience Letters.

[3]  A. Storch,et al.  Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant α-synucleins related to Parkinson's disease , 2006, Neurochemistry International.

[4]  M. Beal,et al.  Mice lacking alpha-synuclein are resistant to mitochondrial toxins , 2006, Neurobiology of Disease.

[5]  W. Langston,et al.  α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates , 2005, Neurobiology of Disease.

[6]  N. Bonini,et al.  Snaring the Function of α-Synuclein , 2005, Cell.

[7]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[8]  E. Masliah,et al.  Lysosomal pathology associated with α‐synuclein accumulation in transgenic models using an eGFP fusion protein , 2005, Journal of neuroscience research.

[9]  Ji-Young Choi,et al.  Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. , 2005, Free radical biology & medicine.

[10]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Feany,et al.  New genetic insights into Parkinson's disease. , 2004, The New England journal of medicine.

[12]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[13]  Christina A. Wilson,et al.  Degradative organelles containing mislocalized α- and β-synuclein proliferate in presenilin-1 null neurons , 2004, The Journal of cell biology.

[14]  E. Masliah,et al.  Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP 1 1 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 2004, Experimental Neurology.

[15]  J. H. Chen,et al.  Endostatin induces autophagic cell death in EAhy926 human endothelial cells. , 2003, Histology and histopathology.

[16]  R. Stern,et al.  Odor Identification Deficits in Diffuse Lewy Body Disease , 2003, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[17]  H. Ischiropoulos.  Oxidative Modifications of α‐Synuclein , 2003 .

[18]  M. Fortini.  Faculty Opinions recommendation of Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. , 2003 .

[19]  A. Manning-Boğ,et al.  Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.

[20]  J. Feldon,et al.  Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. , 2002, Journal of neurobiology.

[21]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[22]  M. Barrachina,et al.  MPP+ increases α-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells , 2002, Brain Research.

[23]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[24]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[25]  M. Farrer,et al.  Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter , 2001, Neurobiology of Disease.

[26]  J. Bauer,et al.  Free 3-Nitrotyrosine Causes Striatal NeurodegenerationIn Vivo , 2001, The Journal of Neuroscience.

[27]  R. P. Maguire,et al.  Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers , 2001 .

[28]  J B Schulz,et al.  Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice , 2001, Journal of neurochemistry.

[29]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[31]  M. Farrer,et al.  Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .

[32]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[33]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[34]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[35]  H. Niznik,et al.  Direct binding and functional coupling of alpha-synuclein to the dopamine transporter , 2000 .

[36]  K. Prasad,et al.  Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells , 2000, Brain Research.

[37]  Y. Yang,et al.  Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation , 2000, Neuroscience.

[38]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[39]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[40]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[41]  R. Burke,et al.  α‐Synuclein expression in substantia nigra and cortex in Parkinson's disease , 1999 .

[42]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[43]  M. Goedert,et al.  Lewy body diseases and multiple system atrophy as α-synucleinopathies , 1998, Molecular Psychiatry.

[44]  M. Polymeropoulos.  Autosomal dominant Parkinson’s disease , 1998, Journal of Neurology.

[45]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[46]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[47]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[48]  Hitoshi Takahashi,et al.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease , 1997, Neuroscience Letters.

[49]  A. Lang,et al.  Olfactory dysfunction in familial parkinsonism , 1997, Neurology.

[50]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[51]  D. Dluzen,et al.  The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice , 1996, Brain Research.

[52]  A. Shamoo,et al.  Identification of the major transport pathway for the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium , 1996, Neuroscience.

[53]  S. Daniel,et al.  The anterior olfactory nucleus in Parkinson's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[54]  I. Kryspin-Exner,et al.  Impaired olfactory function in Parkinson's disease , 1995, The Lancet.

[55]  G. Brownell,et al.  Dopamine Terminal Loss and Onset of Motor Symptoms in MPTP-Treated Monkeys: A Positron Emission Tomography Study with 11C-CFT , 1994, Experimental Neurology.

[56]  M. Pátfalusi,et al.  Methamphetamine protects against MPTP neurotoxicity in C57BL mice. , 1994, European journal of pharmacology.

[57]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[58]  D. Dluzen.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduces norepinephrine concentrations in the olfactory bulbs of male mice , 1992, Brain Research.

[59]  J. Langston,et al.  Lack of major olfactory dysfunction in MPTP‐induced parkinsonism , 1992, Annals of neurology.

[60]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[61]  Y. Itzhak,et al.  Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites. , 1991, Molecular pharmacology.

[62]  A. Lajtha,et al.  Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum. , 1985, European journal of pharmacology.

[63]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[64]  C. Ward,et al.  Olfactory impairment in Parkinson's disease , 1983, Neurology.

[65]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[66]  C. Hawkes,et al.  Olfaction in neurodegenerative disorder. , 2006, Advances in oto-rhino-laryngology.

[67]  I. Ferrer,et al.  Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. , 2006, Neurobiology of aging.

[68]  G. Muntané,et al.  Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease. , 2006, Neuroscience letters.

[69]  D. D. Di Monte,et al.  Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. , 2005, Neurobiology of disease.

[70]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[71]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[72]  R. Krüger,et al.  Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. , 2003, Brain : a journal of neurology.

[73]  H. Ischiropoulos.  Oxidative modifications of alpha-synuclein. , 2003, Annals of the New York Academy of Sciences.

[74]  R. Krüger,et al.  Haploinsufficiency at the α‐synuclein gene underlies phenotypic severity in familial Parkinson’s disease , 2003 .

[75]  D. D. Di Monte.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.

[76]  M. Barrachina,et al.  MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. , 2002, Brain research.

[77]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[78]  M. Farrer,et al.  Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.

[79]  M. Vila,et al.  The parkinsonian toxin MPTP: action and mechanism. , 2000, Restorative neurology and neuroscience.

[80]  Y. Yang,et al.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. , 2000, Neuroscience.

[81]  P. Caroni,et al.  Neuropathology in mice expressing human alpha-synuclein. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[82]  R. Burke,et al.  Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[83]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[84]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Goedert,et al.  Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. , 1998, Molecular psychiatry.

[86]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[87]  K. Suzuki,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compounds on mitochondrial respiration. , 1990, Advances in neurology.

[88]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.